Patient Participation

Elderly patients achieved up to 98% compliance at 18 months on Phase III study.

Now that the industry has been forced to make room for new digital processes, there should be no turning back.

This article sets out a vision of adopting convenient alternative blood sampling approaches that places the needs of the patient at the center and enables active monitoring, before the onset of clinical events, leading to improved healthcare.

Nicole Richie, Global Head Health Equity and Population Science at Genentech/Roche, discusses a renewed strategy in big pharma to incorporate diversity inclusion in clinical trials.

Physicians share their experiences integrating research into practice.

Study designs, coupled with difficulties finding, enrolling and retaining trial participants, further intensify operational challenges and prevent new treatments from getting to market.

While it's important to note that there are areas where the industry can improve, there are unique opportunities of improvement for specific types of sites and the number of studies conducted there.

Andaman7 and Afrisda, Inc. sign partnership agreement to support digital health implementation in Africa.

Centralized medical imaging providers must challenge their current processes to improve patient diversity.

How COVID-19 blazed a new trail for greater patient inclusion.

Affirming and advancing patient engagement and digital transformation.

The role of data science, how it can help us understand patient behavior, and why digital adherence solutions are the future.

Sparked by the pandemic, patients are now leveraging remote technology to take control of their healthcare.

Michele Russell-Einhorn, Chief Compliance Officer at Advarra discusses safety, speed, and ethics in COVID-19 vaccine trials.

Building authentic trust lays at the heart of creating more patient-centric trials.

Understanding the role of social determinants on clinical trial participation and trust.

Co-conveners of the newly formed Decentralized Trials & Research Alliance, Amir Kalali, MD and Craig Lipset discuss the alliance as well as how COVID-19 has impacted the industry.

Hybrid studies, patient-centric tools, and collaborations create big changes for clinical trials and stakeholders during COVID-19.

EVP and General Manager of Hū, April Lewis, discusses why the industry has seen a decline in trial participation and what Hū is doing to combat it.

Eliminating barriers to engage underrepresented populations.

Randomized controlled trials establish strict inclusion and exclusion criteria in an effort to optimize the cohort of trial participants.

Recognizing pre-pandemic pain points, such as patient engagement and protocol development, could lead to post-pandemic trial success.

Evaluating the lessons learned about trial sites from COVID-19 to form new strategies and improve patient safety for the future.

With the assistance of mobile research nursing, in-home visits provide solid alternative to trial participants, especially during COVID-19.

Jody Casey of Elligo Health Research gives insight into the issue of diversity in trials and what needs to be done to correct it.

Practical suggestions for identifying what actionable insights have been impactful on clinical studies.

The pandemic has thus far disproportionally impacted minority populations, and our ongoing failure to adequately represent all patients regardless of demographic background has never been more important to remedy than it is today, writes ACRP Workforce Innovation Officer Beth Harper.

Beyond technology, awareness, and access—cultural competence is key.

Past decades have shown gender-based differences in clinical trial results are often overlooked when considering safety and effectiveness.